These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 16364249

  • 1. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.
    Santos AM, Sousa H, Portela C, Pereira D, Pinto D, Catarino R, Rodrigues C, Araújo AP, Lopes C, Medeiros R.
    Biochem Biophys Res Commun; 2006 Feb 03; 340(1):256-62. PubMed ID: 16364249
    [Abstract] [Full Text] [Related]

  • 2. Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer.
    Santos AM, Sousa H, Pinto D, Portela C, Pereira D, Catarino R, Duarte I, Lopes C, Medeiros R.
    Eur J Cancer; 2006 May 03; 42(7):958-63. PubMed ID: 16542834
    [Abstract] [Full Text] [Related]

  • 3. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome.
    Pinto D, Pereira D, Portela C, da Silva JL, Lopes C, Medeiros R.
    Biochem Biophys Res Commun; 2005 Oct 07; 335(4):1173-8. PubMed ID: 16112085
    [Abstract] [Full Text] [Related]

  • 4. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
    Kim JG, Sohn SK, Chae YS, Song HS, Kwon KY, Do YR, Kim MK, Lee KH, Hyun MS, Lee WS, Sohn CH, Jung JS, Kim GC, Chung HY, Yu W.
    Cancer Chemother Pharmacol; 2009 Jul 07; 64(2):355-60. PubMed ID: 19052714
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome.
    Medeiros R, Pereira D, Afonso N, Palmeira C, Faleiro C, Afonso-Lopes C, Freitas-Silva M, Vasconcelos A, Costa S, Osório T, Lopes C.
    Int J Clin Oncol; 2003 Jun 07; 8(3):156-61. PubMed ID: 12851839
    [Abstract] [Full Text] [Related]

  • 9. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
    Gadducci A, Di Cristofano C, Zavaglia M, Giusti L, Menicagli M, Cosio S, Naccarato AG, Genazzani AR, Bevilacqua G, Cavazzana AO.
    Anticancer Res; 2006 Jun 07; 26(1B):687-93. PubMed ID: 16739339
    [Abstract] [Full Text] [Related]

  • 10. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
    Licitra L, Suardi S, Bossi P, Locati LD, Mariani L, Quattrone P, Lo Vullo S, Oggionni M, Olmi P, Cantù G, Pierotti MA, Pilotti S.
    J Clin Oncol; 2004 Dec 15; 22(24):4901-6. PubMed ID: 15611505
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.
    Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D.
    Cancer; 2009 Jun 01; 115(11):2453-63. PubMed ID: 19322891
    [Abstract] [Full Text] [Related]

  • 13. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
    Gréen H, Söderkvist P, Rosenberg P, Horvath G, Peterson C.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):854-9. PubMed ID: 16467099
    [Abstract] [Full Text] [Related]

  • 14. Association of p53 and p21(CDKN1A/WAF1/CIP1) polymorphisms with oral cancer in Taiwan patients.
    Bau DT, Tsai MH, Lo YL, Hsu CM, Tsai Y, Lee CC, Tsai FJ.
    Anticancer Res; 2007 Feb 01; 27(3B):1559-64. PubMed ID: 17595776
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer.
    Duarte I, Santos A, Sousa H, Catarino R, Pinto D, Matos A, Pereira D, Moutinho J, Canedo P, Machado JC, Medeiros R.
    Biochem Biophys Res Commun; 2005 Aug 26; 334(2):588-92. PubMed ID: 16009345
    [Abstract] [Full Text] [Related]

  • 17. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction?
    Tan XL, Nieters A, Hoffmeister M, Beckmann L, Brenner H, Chang-Claude J.
    Pharmacogenet Genomics; 2007 Aug 26; 17(8):639-45. PubMed ID: 17622940
    [Abstract] [Full Text] [Related]

  • 18. OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer.
    Arcand SL, Provencher D, Mes-Masson AM, Tonin PN.
    Int J Oncol; 2005 Nov 26; 27(5):1315-20. PubMed ID: 16211227
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.